Home  >  News
International
+ Font Resize -

Pfizer plans to hive off OTC healthcare product businesses

Our Bureau, Mumbai
Wednesday, October 11, 2017, 16:00 Hrs  [IST]

Pfizer Inc. has decided strategic alternatives for its consumer healthcare business and considering a range of options including a full or partial separation of the consumer healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. The announcement is part of Pfizer’s continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders.

Pfizer Consumer Healthcare is one of the largest OTC health care products businesses in the world with 2016 revenues of approximately $3.4 billion, operating in more than 90 countries globally. Consumer healthcare markets two of the ten top selling consumer healthcare brands globally – Centrum and Advil. In addition, the business has ten brands that each exceeded $100 million in 2016 sales, and several local brands that are top-ranked in their respective markets.

“Pfizer Consumer Healthcare is a leading player in the largest OTC categories, with iconic brands, robust retail partnerships, global reach and strong fundamentals,” said Ian Read, Pfizer chairman and CEO. “Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company. By exploring strategic options, we can evaluate how best to fuel the future success and expansion of consumer healthcare while simultaneously unlocking potential value for our shareholders.”

Pfizer Consumer Healthcare develops, manufactures and markets leading non-prescription medicines, vitamins, and personal care products. Major categories and product lines viz., Dietary supplements: Centrum, Caltrate, and Emergen-C, Pain management: Advil and Thermacare, Gastrointestinal: Nexium 24 Hour and Preparation H, Respiratory: Robitussin and Advil Cold and Sinus and Personal care: ChapStick and Anbesol.
 
“Consumers are taking more ownership of their health and wellness through OTC products, preventative treatments and alternative health paths,” said Albert Bourla, group president, Pfizer Innovative Health. “Pfizer Consumer Healthcare is playing an important role in changing the world’s well-being. Our colleagues are passionate about empowering consumers around the world to improve their health and wellness through our trusted brands, innovation, and thought leadership.”

Pfizer has engaged Centerview Partners LLC, Guggenheim Securities LLC and Morgan Stanley & Co. LLC as financial advisors for the strategic review process. Pfizer expects that any decision regarding strategic alternatives for Pfizer Consumer Healthcare would be made during 2018. The company does not plan to make any further statements about the strategic review process until a decision has been reached or upon the completion of the strategic review.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :